Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial
Rattachement africain : ru, pl, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: EMPOWER-Lung 3 part 2 trial demonstrated significant survival benefits with cemiplimab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced NSCLC without EGFR, ALK, or ROS1 aberrations. Here, we report 5-year follow-up outcomes. METHODS: Patients were randomized 2:1 to receive cemiplimab (350 mg every 3 wk for up to 108 wk) or placebo plus four cycles of chemotherapy. Primary end point was overall survival (OS); secondary end points included progression-free survival and objective response rate. RESULTS: This study randomized 466 patients to cemiplimab plus chemotherapy (n = 312) or chemotherapy alone (n = 154). After a median follow-up of 60.9 months, median OS was 21.1 months for cemiplimab plus chemotherapy versus 12.9 months for chemotherapy alone (hazard ratio = 0.66 [95% confidence interval: 0.53-0.83], p = 0.0002); median progression-free survival was 8.2 months versus 5.5 months (hazard ratio = 0.58 [95% confidence interval: 0.47-0.72], p < 0.0001); objective response rate was 43.6% versus 22.1%; and complete response was observed in 6.4% of patients (20/312) versus 0% (0/154), respectively. Five-year OS probability was 19.4% for cemiplimab plus chemotherapy versus 8.8% for chemotherapy alone. Efficacy was demonstrated in both squamous and nonsquamous histology. For 22.8% of patients (71/312) who completed 36 cycles of cemiplimab treatment, OS probability was 57.3% at 3 years after treatment completion (approximately 5 y after randomization). Among the total study population, incidence of treatment-emergent adverse events of grade 3 or higher was 49.4% with cemiplimab plus chemotherapy and 32.7% with chemotherapy alone. CONCLUSIONS: With 5-year follow-up, cemiplimab plus chemotherapy continues to demonstrate durable long-term efficacy benefits versus chemotherapy alone with consistent safety profile, as first-line therapy for advanced NSCLC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial
- Date Crossref
- 01/06/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Ministry of Health of the Russian Federation pays non établi dans la noticeOrganisme public
-
Chelyabinsk Regional Clinical Oncology Center pays non établi dans la noticeÉtablissement de santé
-
Polish Mother’s Memorial Hospital Research Institute pays non établi dans la noticeÉtablissement de santé
-
Regeneron (United States) pays non établi dans la noticeEntreprise
-
PAREXEL International (United States) pays non établi dans la noticeEntreprise
-
Acad. F. Todua Medical Center pays non établi dans la noticeÉtablissement de santé
-
LTD High Technology Hospital Med Center pays non établi dans la noticeÉtablissement de santé
-
University Clinic High Technology Medical Centre pays non établi dans la noticeUniversité ou école supérieure
-
Multiprofile Clinic Consilium Medulla pays non établi dans la noticeÉtablissement de santé
-
Private Medical Institution Euromedservice pays non établi dans la noticeStructure de recherche
-
The Institute of Clinical Oncology pays non établi dans la noticeStructure de recherche
-
Kaluga Regional Clinical Oncology Dispensary pays non établi dans la noticeÉtablissement de santé
Ministry of Health of the Russian Federation, Chelyabinsk Regional Clinical Oncology Center et Polish Mother’s Memorial Hospital Research Institute, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.